Testing effectiveness (Phase 2)Study completedNCT03126019What this trial is testingINCB050465 in Relapsed or Refractory Follicular LymphomaWho this might be right forLymphoma Incyte Corporation 126
Testing effectiveness (Phase 2)Active Not RecruitingNCT04533581What this trial is testingStudy of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)Who this might be right forIndolent B-cell Non-Hodgkin's Lymphoma Kyowa Kirin Co., Ltd. 61
Early research (Phase 1)Study completedNCT03498430What this trial is testingCopanlisib Chinese PK StudyWho this might be right forLymphoma, Non-Hodgkin Bayer 13
Large-scale testing (Phase 3)Study completedNCT00329030What this trial is testingRituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401)Who this might be right forLymphoma, B-CellLymphoma, Large-Cell, ImmunoblasticLymphoma, Non-Hodgkin National Heart, Lung, and Blood Institute (NHLBI) 224
Early research (Phase 1)Study completedNCT00161187What this trial is testingIrradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid TumorWho this might be right forCancer University of Medicine and Dentistry of New Jersey 37
Early research (Phase 1)Ended earlyNCT00093704What this trial is testingBortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive LymphomaWho this might be right forLymphomaLymphoproliferative Disorder Jonsson Comprehensive Cancer Center 1
Early research (Phase 1)Active Not RecruitingNCT04447716What this trial is testingAn Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to TreatmentWho this might be right forRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Follicular LymphomaRecurrent Indolent Adult Non-Hodgkin Lymphoma+5 more Thomas Jefferson University 4
Early research (Phase 1)Ended earlyNCT04045028What this trial is testingEvaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin LymphomaWho this might be right forMultiple MyelomaNon-Hodgkin LymphomaB-Cell Lymphoma Genentech, Inc. 41
Testing effectiveness (Phase 2)WithdrawnNCT03602898What this trial is testingComparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell TransplantationWho this might be right forAcute Lymphoblastic Leukemia in RemissionAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeChronic Myelomonocytic Leukemia+10 more Fred Hutchinson Cancer Center
Early research (Phase 1)Not Yet RecruitingNCT07335328What this trial is testingFully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell MalignanciesWho this might be right forB-cell Non Hodgkin Lymphoma Medical College of Wisconsin 24
Testing effectiveness (Phase 2)WithdrawnNCT00881387What this trial is testingRituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to TreatmentWho this might be right forLymphoma University of Miami
Not applicableStudy completedNCT04213209What this trial is testingSpecial Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma"Who this might be right forPeripheral T Cell LymphomaPediatric Hodgkin Lymphoma Takeda 95
Early research (Phase 1)Looking for participantsNCT06875063What this trial is testingGB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHLWho this might be right forNon-hodgkin LymphomaRefractory LymphomaChimeric Antigen Receptor T-cell The First Affiliated Hospital of Xiamen University 45
Testing effectiveness (Phase 2)Study completedNCT00021372What this trial is testingPaclitaxel and Estramustine in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaWho this might be right forLymphoma Fox Chase Cancer Center 25
Testing effectiveness (Phase 2)Looking for participantsNCT07473167What this trial is testingStudy of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma PatientsWho this might be right forRelapsed Large B-cell LymphomaRefractory Large B-cell LymphomaDiffuse Large B-cell Lymphoma (DLBCL)+3 more TICAROS Co., Ltd. 98
Testing effectiveness (Phase 2)Study completedNCT01741792What this trial is testingClinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)Who this might be right forDiffuse Large B-cell Lymphoma Amgen Research (Munich) GmbH 25
Testing effectiveness (Phase 2)Ended earlyNCT00265928What this trial is testingBortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's LymphomaWho this might be right forLymphoma University of Virginia 46
Early research (Phase 1)Study completedNCT01164709What this trial is testingNelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic CancerWho this might be right forLeukemiaLymphomaMature T-cell and Nk-cell Neoplasms+1 more Swiss Cancer Institute 18
Testing effectiveness (Phase 2)Looking for participantsNCT05869279What this trial is testingAllogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic LeukemiaWho this might be right forB-cell NHLCLL Fondazione Matilde Tettamanti Menotti De Marchi Onlus 29
Testing effectiveness (Phase 2)Study completedNCT00059995What this trial is testingMDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed LymphomaWho this might be right forLymphoma Memorial Sloan Kettering Cancer Center